Trial Condition(s):

Acute Coronary Syndrome, Venous thrombosis, Pulmonary Embolism, Atrial Fibrillation

Study of Rivaroxaban use and potential adverse outcomes in routine clinical practice (Sweden)

Bayer Identifier:

17543

ClinicalTrials.gov Identifier:

NCT02468102

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This prospective cohort study will provide information about:
Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first time.
The occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.

Inclusion Criteria
-  All male and female patients who have filled a prescription for rivaroxaban, warfarin, aspirin, clopidogrel, ticlopidine, prasugrel and ticagrelor in any pharmacy in Sweden, between December 9, 2011 and December 31, 2018
Exclusion Criteria
-  For the AF and DVT/PE treatment indications, patients who have filled a prescription for warfarin or another oral anticoagulant at any time between July 1, 2005 and December 9, 2011 will be excluded

Trial Summary

Enrollment Goal
99999
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many Locations

Many Locations, Sweden

Status
Recruiting
 

Trial Design